发明名称 |
Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation |
摘要 |
A solid dosage form of nilotinib is disclosed that comprises: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, said polymer coating said core, wherein disintegration of said solid dosage form is delayed. |
申请公布号 |
AU2012339829(B2) |
申请公布日期 |
2016.05.12 |
申请号 |
AU20120339829 |
申请日期 |
2012.11.12 |
申请人 |
NOVARTIS AG |
发明人 |
BHARDWAJ, UPKAR;BORDAWEKAR, MANGESH SADASHIV;COMFORT, ANN REESE;LI, PING;LI, SHOUFENG;MAKAROV, ALEXEV |
分类号 |
A61K9/00;A61K9/20;A61K9/28 |
主分类号 |
A61K9/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|